AA
AVDL

AlphaMark Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

AlphaMark Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-250
Closed -$2K – 516
2018
Q2 		$2K Hold
250
– – ﹤0.01% 480
2018
Q1 		$2K Buy
+250
New +$2.2K ﹤0.01% 467

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AlphaMark Advisors's AVDL Position: Q3 2018 in Review

AlphaMark Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q3 2018, closing a stake of 250 shares — an estimated $2K sold.

AlphaMark Advisors first reported a position in AVDL in Q1 2018 and held it in 2 quarters. The position peaked at $2K in Q2 2018. 65 funds tracked by Wall St. Rank hold AVDL as of Q3 2018.

  • AlphaMark Advisors reported no remaining Avadel Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • AlphaMark Advisors sold 250 Avadel Pharmaceuticals shares in Q3 2018, an estimated $2K.
  • AlphaMark Advisors first reported a position in Avadel Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • AlphaMark Advisors's Avadel Pharmaceuticals position peaked at $2K in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2018.

Based on AlphaMark Advisors's 13F filing for Q3 2018, filed 5 Nov 2018.